Management of advanced HIV disease: Resistance, antiretroviral brain penetration and malignancies

International Journal of Clinical Practice

Volumn 60, Issue 9, 2006, Pages 1098-1106

  Boffito, Marta ^a   Pillay, D ^b   Wilkins, E ^c  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

Advanced HIV disease; Antiretroviral brain penetration; Malignancy; Resistance

Indexed keywords

AMPRENAVIR; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DIDANOSINE; DOXORUBICIN; EFAVIRENZ; ETOPOSIDE; GLYCOPROTEIN P; INDINAVIR; KETOCONAZOLE; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PACLITAXEL; PROTEINASE INHIBITOR; RETINOIC ACID; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; BLOOD BRAIN BARRIER; BONE MARROW TOXICITY; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM DISEASE; COMORBIDITY; DEATH; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; EARLY DIAGNOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERURICEMIA; INFECTION RISK; IRELAND; ITALY; KAPOSI SARCOMA; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PANCYTOPENIA; PATIENT CARE; PERIPHERAL NEUROPATHY; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SPAIN; UNITED KINGDOM; UNITED STATES; VIRUS TRANSMISSION;

AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASES; DRUG RESISTANCE, VIRAL; EARLY DIAGNOSIS; HIV INFECTIONS; HUMANS; RISK FACTORS; VIRAL LOAD;

EID: 33747164762     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01073.x     Document Type: Review

References (52)

1. Girardi E, Sampaolesi A, Gentile M et al. Increasing proportion of late diagnosis of HIV infection among patients with AIDS in Italy following introduction of combination antiretroviral therapy. J Acquir Immune Defic Syndr 2000; 25: 71-6.
2. Castilla J, Sobrino P, De La Fuente L et al. Late diagnosis of HIV infection in the era of highly active antiretroviral therapy: consequences for AIDS incidence. AIDS 2002; 16: 1945-51.
3. Neal JJ, Fleming P. Frequency and predictors of late HIV diagnosis in the United States, 1994 through 1999. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 24-28 February 2002 (Poster 474-M).
4. Sullivan AK, Curtis H, Sabin A et al. Newly diagnosed HIV infections: review in UK and Ireland. BMJ 2005; 330: 1301-2.
5. BHIVA Writing Committee on behalf of the BHIVA Executive Committee. British HIV Association (BHIVA) Guidelines for the Treatment of HIV-infected Adults with Antiretroviral Therapy: An Update. April 2005. London: BHIVA, 2005.
6. Palella FJ, Deloria-Knoll M, Chmiel JS et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 2003; 138: 620-6.
7. Pao D, Fisher M, Hue S et al. Transmission of HIV-1 during primary infection: Relationship to sexual risk and sexually transmitted infections. AIDS 2005; 19: 85-90.
8. Phillips AN, Dunn D, Sabin C et al. Long-term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005; 19: 487-94.
9. Pillay D, Green H, Matthias R et al. UK Collaborative Group on HIV drug resistance. Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. J Infect Dis 2005; 192: 967-73.
10. Health Protection Agency. Transmitted Infections in the United Kingdom in 2003. Annual Report 2004. London: HPA, 2004. http://www.hpa.org.uk/ infections/topics_az/hiv_and_sti/publications/annual2004/annual2004.htm.
11. Dunn DT, Green H, Matthias R et al. Prevalence of reduced drug susceptibility in treatment-naïve patients in the UK. Antivir Ther 2004; 9: S107.
12. Health Protection Agency. HIV/sexually transmitted infections (STIs). An update on HIV drug resistance in the United Kingdom. CDR Wkly 2004; 14. News. http://www.hpa.org.uk/cdr/PDFfiles/2004/cdr4804.pdf.
13. Johnson VA, Brun-Vezinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 2005; 13: 51-7.
14. Kuiken C, Korber B, Shafer RW et al. HIV sequence databases. AIDS Rev 2003; 5: 52-61.
15. Cane P, Chrystie I, Dunn D et al. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 2005; 331: 1368.
16. Little SJ, Holte S, Routy JP et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347: 385-94.
17. Pao D, Andrady U, Clarke J. Long-term persistence of primary care genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr 2004; 37: 1570-3.
18. Pillay D, Bhaskaran K, Jurriaans S et al. The impact of transmitted drug resistance on the natural history of HIV infection and response to firstline therapy. AIDS 2006; 20: 21-8.
19. Sacktor N, McDermott M, Marder K et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 2002; 8: 136-42.
20. Ellis RJ, Gamst AC, Capparelli E et al. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology 2000; 54: 927-36.
21. d'Arminio Moforte A, Cinque P, Morcroft A et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 2004; 55: 320-8.
22. De Luca A, Ciancio BC, Larussa D et al. Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals. Neurology 2002; 59: 342-7.
23. Solas C, Lafeullade A, Halfon P et al. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47: 238-43.
24. Antinori A, Giancola ML, Grisetti S et al. Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1 infected patients. AIDS 2002; 16: 1867-76.
25. Pereira CF, Nottet HSLM. The blood-brain barrier in HIV-associated dementia. Science Online: Neuro AIDS 2000; 3: 1-8.
26. Boffito M, Back DJ, Blaschke TF et al. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses 2003; 19: 825-35.
27. Choo EF, Leake B, Wandel C et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-protease inhibitors into brain and testes. Drug Metab Dispos 2000; 28: 655-60.
28. Khaliq Y, Gallicano K, Venance S et al. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus. Clin Pharmacol Ther 2000; 68: 637-46.
29. Tashima KT, Caliendo AM, Ahmad M et al. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1 infected patients receiving combination therapy. J Infect Dis 1999; 180: 862-4.
30. van Praag RM, Weverling GJ, Portegies P et al. Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. AIDS 2000; 14: 1187-94.
31. Haas DW, Johnson B, Nicotera J et al. Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma. Antimicrob Agents Chemother 2003; 47: 2131-7.
32. Gisolf EH, Jurriaans S, Pelgrom J et al. The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. Prometheus Study Group. AIDS 2000; 14: 405-13.
33. Murphy R, Currier J, Gerber J et al. Antiviral activity and pharmacokinetics of amprenavir with or without zidovudine/3TC in the cerebral spinal fluid of HIV-infected adults. Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 30 January-2 February 2002 (Abstract 314).
34. Lafeuillade A, Solas C, Halfon P et al. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations. HIV Clin Trials 2002; 3: 27-35.
35. van den Brande G, Marquie-Beck J, Capparelli E et al. Kaletra independently reduces HIV replication in cerebrospinal fluid. Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 22-25 February 2005 (Abstract 403).
36. Eggers C, Hertog K, Sturenburg H et al. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration. AIDS 2003; 17: 1897-906.
37. Clifford GM, Polesel J, Rickenbach M et al. Cancer risk in the Swiss HIV cohort study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97: 425-32.
38. Gallagher B, Wang Z, Schymura MJ et al. Cancer incidence in New York State acquired immunodeficiency syndrome patients. Am J Epidemiol 2001; 154: 544-56.
39. Mbulaiteye SM, Biggar RJ, Goedert JJ et al. Cancer risk in elderly persons with HIV/AIDS. J Acquir Immune Defic Syndr 2003; 32: 527-33.
40. Bedimo R, Chen RY, Accortt NA et al. Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002. Clin Infect Dis 2004; 39: 1380-4.
41. Ledergerberger B, Egger M, Erard V et al. AIDS-related opportunistic illnesses occurring after the initiation of potent antiretroviral therapy. The Swiss HIV cohort study. JAMA 1999; 282: 2220-6.
42. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92: 1823-30.
43. Moorcroft A, Katlama C, Johnson AM et al. AIDS across Europe, 1994-1998: the EuroSIDA study. Lancet 2000; 356: 291-6.
44. Diamond C, Taylor TH, Culver HA. Decreased cases of and improved survival from AIDS-associated non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy. Eleventh Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 8-11 February 2004 (Abstract 786).
45. Hoffmann C, Tabrizian S, Wolf E et al. Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS 2001; 15: 2119-27.
46. Portsmouth S, Stebbing J, Gill J et al. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. AIDS 2003; 17: F17-22.
47. Grabar S, Abraham B, Mahamat A et al. Incidences of Kaposi's sarcoma in the HAART era and comparison of different HAART regimens. Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 22-25 February 2005 (Abstract 903).
48. Lascaux AS, Hemery F, Goujard C et al. Beneficial effects of highly active antiretroviral therapy on the prognosis of AIDS-related systemic non-Hodgkin's lymphomas. AIDS Res Hum Retroviruses 2005; 21: 214-20.
49. Stebbing J, Marvin V, Bower M. The evidence-based treatment of AIDS-related non-Hodgkin's lymphoma. Cancer Treat Rev 2004; 30: 249-53.
50. Editorial. HIV-associated lymphoma: promising new results, but with toxicity. Blood 2005; 105: 1842.
51. Bower M, Powles T, Stebbing J et al. Potential antiretroviral drug interactions with cyclophosphamide, doxorubicin, and etoposide. J Clin Oncol 2005; 23: 1328-9.
52. Pozniak AL, Miller RF, Lipman MCI et al. on behalf of the BHIVA Guidelines Writing Committee. BHIVA Treatment Guidelines for TB/HIV Infection. London: BHIVA, 2005.